Bioseeker, Feb 2012 AnalyticalTool - Apoptosis in Oncology "AnalyticalTool - Apoptosis in Oncology" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in apoptotic drug
Bioseeker, Jan 2012, Pages: 4377
is based on the following publication:
A Decision Support Tool for Optimizing The Colorectal Cancer Pipeline: From Research and Development to Market
Part II: Apoptosis
The apoptotic cancer drug report part
Bioseeker, Dec 2011, Pages: 3579
II: Apoptosis
The apoptotic cancer drug report part comprises defined and up to date development strategies for 234 drugs in oncology within the portfolio of 158 companies world-wide, from Ceased
Bioseeker, Jan 2012, Pages: 4468
on the following publication:
A Decision Support Tool for Optimizing The Leukemia Pipeline: From Research and Development to Market
Part II: Apoptosis
The apoptotic cancer drug report part comprises defined and up
Bioseeker, Dec 2011, Pages: 3670
of leukemia.
This part is based on the following publication:
A Decision Support Tool for Optimizing The Leukemia Pipeline: From Research and Development to Market
Part II: Apoptosis
The apoptotic cancer drug
Bioseeker, Jan 2012, Pages: 4644
is based on the following publication:
Lung Cancer: A Decision Support Tool for Optimizing the Pipeline from Research To Market
Part II: Apoptosis
The apoptotic cancer drug report part comprises defined
Bioseeker, Dec 2011, Pages: 3846
and and three subindications of lung cancer.
This part is based on the following publication:
Lung Cancer: A Decision Support Tool for Optimizing the Pipeline from Research To Market
Part II: Apoptosis
Bioseeker, Jan 2012, Pages: 4275
on the following publication:
A Decision Support Tool for Optimizing The Lymphoma Pipeline: From Research and Development to Market
Part II: Apoptosis
The apoptotic cancer drug report part comprises defined and up
Bioseeker, Dec 2011, Pages: 3477
of lymphoma.
This part is based on the following publication:
A Decision Support Tool for Optimizing The Lymphoma Pipeline: From Research and Development to Market
Part II: Apoptosis
The apoptotic cancer drug
Bioseeker, Jan 2012, Pages: 4098
Support Tool for Optimizing the Melanoma Pipeline: From Research and Development to Market
Part II: Apoptosis
The apoptotic cancer drug report part comprises defined and up to date development strategies
Bioseeker, Dec 2011, Pages: 3300
on the following publication:
A Decision Support Tool for Optimizing the Melanoma Pipeline: From Research and Development to Market
Part II: Apoptosis
The apoptotic cancer drug report part comprises defined and up
Bioseeker, Jan 2012, Pages: 4159
on the following publication:
A Decision Support Tool for Optimizing the Prostate Cancer Pipeline: From Research and Development to Market
Part II: Apoptosis
The apoptotic cancer drug report part comprises defined
Bioseeker, Dec 2011, Pages: 3361
in prostate cancer.
This part is based on the following publication:
A Decision Support Tool for Optimizing the Prostate Cancer Pipeline: From Research and Development to Market
Part II: Apoptosis
Bioseeker, Jan 2012, Pages: 3980
: Apoptosis
The apoptotic cancer drug report part comprises defined and up to date development strategies for 234 drugs in oncology within the portfolio of 158 companies world-wide, from Ceased to Marketed
Bioseeker, Dec 2011, Pages: 3182
in this report:
Part I: Apoptosis
The apoptotic cancer drug report part comprises defined and up to date development strategies for 234 drugs in oncology within the portfolio of 158 companies world-wide, from
Bioseeker, Dec 2011, Pages: 4617
II: Apoptosis
The apoptotic cancer drug report part comprises defined and up to date development strategies for 234 drugs in oncology within the portfolio of 158 companies world-wide, from Ceased
Bioseeker, Dec 2011, Pages: 4708
subindications of leukemia.
This part is based on the following publication:
A Decision Support Tool for Optimizing The Leukemia Pipeline: From Research and Development to Market
Part II: Apoptosis
The apoptotic
Bioseeker, Dec 2011, Pages: 4884
and and three subindications of lung cancer.
This part is based on the following publication:
Lung Cancer: A Decision Support Tool for Optimizing the Pipeline from Research To Market
Part II: Apoptosis
Bioseeker, Dec 2011, Pages: 4515
subindications of lymphoma.
This part is based on the following publication:
A Decision Support Tool for Optimizing The Lymphoma Pipeline: From Research and Development to Market
Part II: Apoptosis
The apoptotic
Bioseeker, Dec 2011, Pages: 4338
.
This part is based on the following publication:
A Decision Support Tool for Optimizing the Melanoma Pipeline: From Research and Development to Market
Part II: Apoptosis
The apoptotic cancer drug report part